© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Expert Interviews
UPCOMING SERIES: Increasing Awareness Around the Genetic Components of ALS
December 23, 2022
Jennifer Roggenbuck, MS, CGC, navigates the testing, diagnosis, and management of patients with ALS.
Incidence and Prevalence of MDR HIV in the US
December 12, 2022
Dr McCray shares an encounter with “Patient X”, highlighting the barriers and challenges associated with MDR therapies in HIV treatment.
Overview of Multi-Drug Resistant (MDR) HIV
December 12, 2022
Dr McCray shares an encounter with “Patient X”, highlighting the barriers and challenges associated with MDR therapies in HIV treatment.
Evolving Landscape of SMA Treatment
December 01, 2022
In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.
Trajectory of Demodex Blepharitis Treatment Pathways
November 29, 2022
Douglas K. Devries, OD, shares his final insights, highlighting prospective emerging treatments for Demodex blepharitis.
Considerations for Payers Covering Combination Treatment of SMA and the Impact of Utilization Management
November 28, 2022
John Brandsema, MD, and Julie Parsons, MD, discuss considerations for combination SMA treatment and factors impacting SMA care pathways, such as prior authorization and multistep therapies.
Bringing Cancer Screenings to the Community Can Increase Today's Diagnosis Number and Get Patients to Care Sooner
November 24, 2022
In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.
What the 'Pathway Approach' Can Do to Improve Health Outcomes, Reduce Testing Delays For Cancer Care
November 23, 2022
Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.
The Role of Switching and Combination Therapy in SMA Regimens
November 23, 2022
Medical experts provide insights on factors impacting SMA treatment strategies.
The Outcomes of Shortening the Gap on Time of Care After Receiving a Diagnosis
November 22, 2022
Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, talks about why shortening this gap is critical to ensuring better patient outcomes and shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. This is the first part of a three-part video series.